睿知中国医院研究地图
候选清单

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院肿瘤医院深圳医院Cancer Hospital CAMS – Shenzhen深圳医院页面
  2. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
  3. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07689851,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

    入选标准第 2 条

  3. Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies.

    排除标准第 2 条

  4. ECOG performance status of 0-1.

    入选标准第 5 条

  5. Hemoglobin ≥90 g/L;

    入选标准第 8 条

    Absolute neutrophil count ≥1.5 × 10⁹/L;

    入选标准第 10 条

    Platelet count ≥100 × 10⁹/L;

    入选标准第 11 条

    Serum creatinine ≤1.0 × upper limit of normal (ULN);

    入选标准第 12 条

    Blood urea nitrogen (BUN) ≤1.0 × ULN;

    入选标准第 13 条

    Alanine aminotransferase (ALT) ≤1.5 × ULN;

    入选标准第 14 条

    Aspartate aminotransferase (AST) ≤1.5 × ULN;

    入选标准第 15 条

    Alkaline phosphatase (ALP) ≤1.5 × ULN;

    入选标准第 16 条

    Total bilirubin (TBIL) ≤1.5 × ULN;

    入选标准第 17 条

  6. At least one measurable lesion according to RECIST version 1.1.

    入选标准第 6 条

  7. Congenital or acquired immunodeficiency, including HIV infection, or a history of organ transplantation or allogeneic hematopoietic stem cell transplantation.

    排除标准第 10 条

    Active hepatitis B infection (HBV DNA ≥2,000 IU/mL), active hepatitis C infection, or active tuberculosis.

    排除标准第 11 条

  8. Pregnant or breastfeeding women.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07689851,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female participants aged 18 to 75 years.
  2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
  3. Unresectable locally advanced or metastatic gastric cancer, with primary and metastatic lesions amenable to radiotherapy (excluding patients with brain metastases or extensive metastatic disease).
  4. HER2-negative disease.
  5. ECOG performance status of 0-1.
  6. At least one measurable lesion according to RECIST version 1.1.
  7. Adequate organ function, including:
  8. Hemoglobin ≥90 g/L;
  9. White blood cell count ≥3.5 × 10⁹/L;
  10. Absolute neutrophil count ≥1.5 × 10⁹/L;
  11. Platelet count ≥100 × 10⁹/L;
  12. Serum creatinine ≤1.0 × upper limit of normal (ULN);
  13. Blood urea nitrogen (BUN) ≤1.0 × ULN;
  14. Alanine aminotransferase (ALT) ≤1.5 × ULN;
  15. Aspartate aminotransferase (AST) ≤1.5 × ULN;
  16. Alkaline phosphatase (ALP) ≤1.5 × ULN;
  17. Total bilirubin (TBIL) ≤1.5 × ULN;
  18. Negative urine protein;
  19. Normal coagulation function.
  20. No contraindications to immunotherapy.
  21. No history of hypersensitivity to fluoropyrimidines or platinum-based agents.
  22. No prior surgery, chemotherapy, immunotherapy, or other antitumor therapy for gastric or gastroesophageal junction cancer since diagnosis.
  23. No previous radiotherapy to the intended irradiation sites.
  24. Ability to understand and willingness to sign a written informed consent form.

排除标准:Exclusion Criteria:

  1. Brain metastases or extensive metastatic disease.
  2. Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies.
  3. Severe autoimmune diseases, including but not limited to active inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or autoimmune vasculitis (e.g., Wegener's granulomatosis).
  4. Symptomatic interstitial lung disease or active infectious/non-infectious pneumonitis.
  5. Conditions associated with an increased risk of gastrointestinal perforation, including active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis, or other known risk factors.
  6. History of another malignancy, except adequately treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
  7. Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or unstable cardiac arrhythmia.
  8. Any physical examination findings, laboratory abnormalities, or uncontrolled medical conditions that, in the investigator's judgment, may interfere with study outcomes or increase the risk of treatment-related complications.
  9. Pregnant or breastfeeding women.
  10. Congenital or acquired immunodeficiency, including HIV infection, or a history of organ transplantation or allogeneic hematopoietic stem cell transplantation.
  11. Active hepatitis B infection (HBV DNA ≥2,000 IU/mL), active hepatitis C infection, or active tuberculosis.
  12. Receipt of any live or other prohibited vaccines within 4 weeks before study treatment. Seasonal inactivated influenza vaccines are permitted, whereas intranasal live attenuated influenza vaccines are not permitted.
  13. Concurrent treatment with other immunosuppressive agents, chemotherapy, investigational drugs, or long-term systemic corticosteroids.
  14. Psychiatric disorders, substance abuse, or social conditions that may compromise treatment compliance, as determined by the investigator.
  15. Known hypersensitivity or contraindication to any study treatment.

引自 ClinicalTrials.gov, NCT07689851, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07689851,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07689851